Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 90.02%. However, over the last six months, the performance has been weaker by 76.29%. The price of TGTX increased 4.19% over the last 30 days. And in the last five days, it has surged by 1.36%.
TG Therapeutics Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $36.84 on 11/25/24, while the lowest price for the same period was registered at $12.84 on 02/21/24.
52-week price history of TGTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. TG Therapeutics Inc’s current trading price is -11.90% away from its 52-week high, while its distance from the 52-week low is 152.77%. The stock’s price range during this period has varied between$12.84 and $36.84. The TG Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.81 million for the day, a figure considerably lower than their average daily volume of 3.45 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
TG Therapeutics Inc (TGTX) has experienced a quarterly rise of 39.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.05B and boasts a workforce of 264 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 25.98, with a change in price of +12.58. Similarly, TG Therapeutics Inc recorded 3,496,151 in trading volume during the last 100 days, posting a change of +63.66%.
TGTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TGTX stands at 1.32. Similarly, the long-term debt-to-equity ratio is also 1.31.
TGTX Stock Stochastic Average
As of today, TG Therapeutics Inc’s raw stochastic average for the last 50 days stands at 70.38%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 30.02%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 18.38% and 31.04%, respectively.
